Navigation Links
Topaz Pharmaceuticals' Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
Date:7/11/2011

HORSHAM, Pa., July 11, 2011 /PRNewswire/ -- In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.  The data were presented in a poster presentation on Saturday, July 9, 2011 at the 37th Annual Meeting of the Society for Pediatric Dermatology in Baltimore, Maryland.  

"These data build on our earlier work showing this ivermectin formulation is active against head lice," said John M. Clark, Ph.D., Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst.  "The data suggest that a single treatment with 0.5% ivermectin cream has the potential to fully break the head louse life cycle.   If approved by the FDA, ivermectin cream has the potential to provide physicians with an attractive treatment option."  

In the study, permethrin resistant head lice were allowed to lay eggs in tufts of human hair.  Adult lice were removed and the tufts with eggs were exposed to 0.5% ivermectin cream, to vehicle only, or to unformulated, diluted ivermectin. After a 10-minute exposure, tufts were thoroughly rinsed and incubated.  Any hatched lice were placed onto new tufts and moved to a feeding cup.  The hatchability of treated eggs was not affected by ivermectin. No differences were detected between the mortality rate of eggs exposed to 0.5% ivermectin cream and those exposed to unformulated ivermectin.  The percent of hatched lice from eggs exposed to 0.5% ivermectin cream that took a blood meal, relative to eggs exposed to placebo, was significantly decreased (by 82-95%).  All hatched lice from eggs treated with 0.5% ivermectin cream died within 48 hours.  

About Ivermectin

Ivermectin is a broad-spectrum antiparasitic agent.  Its known mechanism of action is that it binds selectively to certain ion channels present in invertebrate nerve and muscle cells but not present in mammals. The resulting increase in permeability of the cell membrane causes the death of certain parasites.  First developed from a soil bacterium, widespread oral use of ivermectin, under the brand name Mectizan®, began in 1987 in sub-Saharan Africa to control river blindness (onchocerciasis) in humans.  More than one billion treatments of oral ivermectin have been administered to help alleviate the suffering caused by river blindness and lymphatic filariasis.  On June 7, 2011, FDA accepted the new drug application of Topaz Pharmaceuticals for the use of a novel topical form of ivermectin as a potential therapy to treat head lice.  This submission is presently under review by FDA.

About Topaz Pharmaceuticals

Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice infestations in children and adults which affect between six and 12 million people every year. Topaz has completed two phase 3 studies of ivermectin and has filed its new drug application for this potential indication. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences.  For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com.

Contact Information
E. Blair Schoeb
Tel: 908-277-0386
blair@biotechcomm.com


'/>"/>
SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
2. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
3. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
4. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
5. TOPAZ Technologies and ML Weekes & Company Announce Partnership
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
8. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):